Addition of Nivolumab to Neoadjuvant Chemotherapy in NSCLC: Results of CheckMate-816
Patrick FordePlatinum-based chemotherapy, given either before (neoadjuvant) or after (adjuvant) surgery for stage II and III NSCLC is associated with a 5% improvement in long-term survival. Despite consensus guidelines recommending its […] Read more
Veterans Health Administration’s Lung Precision Oncology Program Helps Individualize Treatment
Michael Kelley+more
Lung cancer is not only the leading cause of cancer deaths in the United States, with nearly 229,000 people diagnosed annually, but is also the deadliest cancer affecting patients of […] Read more
A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated […] Read more
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
Lizza Hendriks+more
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated […] Read more
Second-Line, Biomarker-Driven Therapies for Squamous NSCLC: Report on Lung-MAP SWOG S1400
Julia Judd+more
The Lung Master Protocol (Lung-MAP; S1400) was a biomarker-driven master protocol. This trial was originally designed to address the relative paucity of effective, targeted therapies in squamous cell lung cancer, […] Read more
America’s decades-long war on smoking has been remarkably successful in reducing smoking rates, but the unintended consequences include stigmatizing people who smoke and people with lung cancer. Sadly, those dealing […] Read more
China’s Domestic PD-1/PD-L1 Inhibitors Demanding Global Attention
Leah LawrenceThe growth of these domestic drugs should shine a light on the lack of diversity in many international clinical trials in immunotherapy. Read more
Surgical Outcomes of CheckMate816 Support Use of Neoadjuvant Nivolumab Plus Chemotherapy for NSCLC
Leah LawrencePatients treated with neoadjuvant combination nivolumab plus chemotherapy who had resectable NSCLC underwent surgical resection at similar rates and timeframes to those undergoing neoadjuvant chemotherapy, according to a presentation of […] Read more
VIOLET Data Establishes VATS as Standard for Early-Stage Resectable NSCLC
Leah LawrenceA presentation of updated results from the VIOLET study comparing video-assisted thoracoscopic surgery (VATS) with open lobectomy showed that improvements in pain, in-hospital complications, and shorter hospital stay previously reported […] Read more
3D Model of Lung Nodules Reduces Anxiety for Patients While Helping Them Understand Their Cancer Risk
Beth Fand IncollingoThousands of Americans each year learn that CT chest screening has identified nodules on their lungs and, as a result, they often experience distress, fear, and confusion about their cancer […] Read more